Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)

Trial Details

NCT ID
NCT04305548
Phase
PHASE2
Sponsor
Italian Sarcoma Group
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Trabectedin
Locations (sample)
  • Prato, Firenze, Italy|43.8805,11.09699
  • Roma, RM, Italy|44.99364,11.10642
  • Candiolo, Torino, Italy|44.95858,7.59812
  • Bologna, Italy|44.49381,11.33875
  • Milan, Italy|45.46427,9.18951

Key Eligibility Criteria

  • Age ≥ 16 years old
  • Histological centrally confirmed diagnosis of skeletal or extra-skeletal MCS with the documented presence of HEY1-NCOA2 fusion
  • Locally advanced disease and/or metastatic disease
  • Measurable or evaluable disease with RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →